Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Diagnostic Antigens for the Identification of Latent Tuberculosis Infection
Case ID:
TAB-2773
Web Published:
12/6/2022
CDC researchers have developed technology for sero-diagnosis of typically symptomless latent stage tuberculosis disease, posing a threat to individuals under immunosuppressive or anti-inflammatory therapies. Specifically, this diagnostic approach exploits
M. tuberculosis
secreted latency specific antigens, such as alpha-crystallin, in the blood or urine of patients. This type of test could easily be developed into an inexpensive dip-stick format with high specificity (no cross-reactivity with other mycobacteria), rapidity, and sensitivity (fewer bacteria needed for a positive identification). Because secreted antigens are recognized more readily by the immune system, serum-derived antibodies to these antigens can correspondingly be used for diagnostic or research use.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Direct Link:
https://canberra-ip.technologypublisher.com/tech/Diagnostic_Antigens_for_the_ Identification_of_Latent_Tuberculosis_Infection
Keywords:
ANTIGENS
CDC Docket Import
CDC Docket Import CDC Prosecuting
DA3XXX
DAXXXX
DC4XXX
DCXXXX
DDXXXX
DEXXXX
diagnostic
DXXXXX
Granuloma
Human
IA3XXX
Identification
Latent
Methods
Model
OID-NCHHSTP-DTE
TUBERCULOSIS
VAXXXX
Vitro
VJXXXX
WBXXXX
WFXXXX
WIXXXX
XAXXXX
XCXXXX
YBXXXX
YDXXXX
Bookmark this page
Download as PDF
For Information, Contact:
Jeremiah Mitzelfelt
LPM
NIH Technology Transfer
301-443-8518
jeremiah.mitzelfelt@nih.gov